TY - JOUR
T1 - Rationally manipulating molecular planarity to improve molar absorptivity, NIR-II brightness, and photothermal effect for tumor phototheranostics
AU - Song, Chaoqi
AU - Yang, Shiping
AU - Chi, Yajing
AU - Zhao, Tingxing
AU - Zhang, Ruili
AU - Li, Hongbo
AU - Wu, Jinting
AU - Zhang, Jianguo
AU - Lam, Jacky W.Y.
AU - Jia, Qian
AU - Tang, Ben Zhong
AU - Wang, Zhongliang
N1 - Publisher Copyright:
© 2025 Elsevier Ltd
PY - 2025/7
Y1 - 2025/7
N2 - The secondary near-infrared region (NIR-II) fluorescence imaging-guided photothermal therapy (PTT) offers a noninvasive and light-controllable treatment option for deep-seated cancers. However, the development of NIR-II photothermal agents (NIR-II PTAs) that possess the desired properties of high molar absorption coefficient (ε), fluorescence quantum yield (QY), and photothermal conversion efficiency (PCE) remain a challenge due to the contradiction between radiative and nonradiative processes. Herein, we propose a novel side-chain heteroatom substitution engineering strategy to simultaneously enhance ε, QY, and PCE by modifying the molecular planarity. Remarkably, by increasing the number of oxygen atoms in the alkyl chains from DTIC, DO1TIC, to DO2TIC, the D−A interaction was enhanced and the molecular planarity was optimized. Theoretical calculations indicated that DO2TIC has a smaller energy gap and closer packing, which may lead to effective regulation of radiative and nonradiative transition processes. Notably, we achieved the excellent ε value of 2.61 × 105 M−1 cm−1 for the NIR-II PTA from DO2TIC, which is attributed to the enhanced molecular planarity. This value surpasses that of most previously developed NIR-II PTAs, resulting in boosted QY and PCE in its nanoparticle state. With these advantages, DO2TIC NPs demonstrated high signal-to-background ratio (SBR = 13.50) imaging of the vascular system and NIR-II imaging-guided PTT for effective tumor elimination using a 1064 nm laser. This study provides a new perspective for developing versatile NIR-II excited phototheranostic systems, enabling potent bioimaging and cancer therapy.
AB - The secondary near-infrared region (NIR-II) fluorescence imaging-guided photothermal therapy (PTT) offers a noninvasive and light-controllable treatment option for deep-seated cancers. However, the development of NIR-II photothermal agents (NIR-II PTAs) that possess the desired properties of high molar absorption coefficient (ε), fluorescence quantum yield (QY), and photothermal conversion efficiency (PCE) remain a challenge due to the contradiction between radiative and nonradiative processes. Herein, we propose a novel side-chain heteroatom substitution engineering strategy to simultaneously enhance ε, QY, and PCE by modifying the molecular planarity. Remarkably, by increasing the number of oxygen atoms in the alkyl chains from DTIC, DO1TIC, to DO2TIC, the D−A interaction was enhanced and the molecular planarity was optimized. Theoretical calculations indicated that DO2TIC has a smaller energy gap and closer packing, which may lead to effective regulation of radiative and nonradiative transition processes. Notably, we achieved the excellent ε value of 2.61 × 105 M−1 cm−1 for the NIR-II PTA from DO2TIC, which is attributed to the enhanced molecular planarity. This value surpasses that of most previously developed NIR-II PTAs, resulting in boosted QY and PCE in its nanoparticle state. With these advantages, DO2TIC NPs demonstrated high signal-to-background ratio (SBR = 13.50) imaging of the vascular system and NIR-II imaging-guided PTT for effective tumor elimination using a 1064 nm laser. This study provides a new perspective for developing versatile NIR-II excited phototheranostic systems, enabling potent bioimaging and cancer therapy.
KW - Cancer theranostics
KW - Molecular planarity
KW - NIR-II fluorescence imaging
KW - NIR-II photothermal therapy
UR - https://www.scopus.com/pages/publications/85216192926
U2 - 10.1016/j.biomaterials.2025.123113
DO - 10.1016/j.biomaterials.2025.123113
M3 - Article
C2 - 39879842
AN - SCOPUS:85216192926
SN - 0142-9612
VL - 318
JO - Biomaterials
JF - Biomaterials
M1 - 123113
ER -